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ABSTRACT
Influenza A virus (IAV) infection frequently causes hospitalization andmortality due to severe immunopathology. Annual vacci-
nation and antiviral drugs are the current countermeasures against IAV infection, but they have a limited efficacy against new
IAV variants. Here, we show that intranasal pretreatment with Fc-fused interleukin-7 (IL-7–mFc) protects mice from lethal IAV
infections. The protective activity of IL-7–mFc relies on transcytosis via neonatal Fc receptor (FcRn) in the lung and lasts for sev-
eral weeks. Introduction of IL-7–mFc alters pulmonary immune environments, leading to recruitment of T cells from circulation
and their subsequent residency as tissue-resident memory-like T (TRM-like) cells. IL-7–mFc-primed pulmonary TRM-like cells
contribute to protection upon IAV infection by dual modes. First, TRM-like cells, although not antigen specific but polyclonal,
attenuate viral replication at the early phase of IAV infection. Second, TRM-like cells augment expansion of IAV-specific cyto-
toxic T lymphocytes (CTLs), in particular at the late phase of infection, which directly control viruses. Thus, accelerated viral
clearance facilitated by pulmonary T cells, which are either antigen specific or not, alleviates immunopathology in the lung and
mortality from IAV infection. Depleting a subset of pulmonary T cells indicates that both CD4 and CD8 T cells contribute to
protection from IAV, although IL-7-primed CD4 T cells have a more prominent role. Collectively, we propose intranasal IL-7–
mFc pretreatment as an effective means for generating protective immunity against IAV infections, which could be applied to a
potential prophylaxis for influenza pandemics in the future.
IMPORTANCE
Themajor consequence of a highly pathogenic IAV infection is severe pulmonary inflammation, which can result in organ fail-
ure and death at worst. Although vaccines for seasonal IAVs are effective, frequent variation of surface viral proteins hampers
development of protective immunity. In this study, we demonstrated that intranasal IL-7–mFc pretreatment protected immuno-
logically naive mice from lethal IAV infections. Intranasal pretreatment with IL-7–mFc induced an infiltration of T cells in the
lung, which reside as effector/memory T cells with lung-retentive markers. Those IL-7-primed pulmonary T cells contributed to
development of protective immunity upon IAV infection, reducing pulmonary immunopathology while increasing IAV-specific
cytotoxic T lymphocytes. Since a single treatment with IL-7–mFc was effective in the protection against multiple strains of IAV
for an extended period of time, our findings suggest a possibility that IL-7–mFc treatment, as a potential prophylaxis, can be de-
veloped for controlling highly pathogenic IAV infections.
Influenza A virus (IAV) has caused seasonal epidemics and fourpandemics in the last century, which threaten the global public
health (1). More recently, it has been reported that avian IAV
variants, including H5N1 and H7N9, can cross-infect humans
with higher mortality than other strains of human-infectious IAV
(2). Although the human-to-human transmission of avian IAV
variants has not been involved in themajor cases yet, the potential
generation of new IAV strains against humans who have no pre-
existing immunity raises the risk of pandemic emergence (3). Al-
though an annual vaccination for specific IAV variants is the cur-
rent primary choice for seasonal influenza control, there are
limitations to this strategy, such as production problems and low
efficacies, and vaccines are unlikely to be available in time toman-
age new antigenic variants (4). Antiviral drugs, such as neuramin-
idase inhibitors, reduce progression to more severe complica-
tions, especially when treatment is within 2 to 3 days of infection
(5). However, new variants that are resistant to existing antiviral
drugs are emerging and might limit the effectiveness of antiviral
drugs in the future (6). Thus, there is an urgent need for an alter-
native strategy against highly pathogenic IAV.
Induction of both innate and adaptive immune responses is
crucial for the control of viremia after IAV infection.However, the
current understanding of IAV infection suggests that excessive
host immune responses lead to immunopathology followed by
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respiratory dysfunction and mortality (7, 8). Previous studies of
pandemic H1N1 infection have suggested that excess production
of cytokines and chemokines, such as granulocyte colony-stimu-
lating factor (G-CSF), interleukin-6 (IL-6), IL-8, IL-10, IP-10, and
monocyte chemoattractant protein-1 (MCP-1), caused severe im-
munopathology, including excessive recruitment of neutrophils
andmononuclear cells in the lungs, which resulted in severe com-
plications leading to death (9, 10). Thus, immune-modulatory
strategies as therapeutics to reduce severe complications are to be
investigated for the cure against IAV infection. Accordingly, re-
cent experimental studies showed successful reduction of IAV-
induced mortality by use of immune-modulatory agents, includ-
ing a Toll-like receptor 4 antagonist, the sphingosine analog
AAL-R, and amembrane-associated prostaglandin E2 (PGE2) syn-
thase-1 inhibitor (11–14). However, these approaches required
repeated treatments due to their transient effectiveness. Thus, the
development of long-term and universal protective agents against
IAV infection is strongly needed.
Interestingly, several clinical observations suggest that severe
immunopathology is frequently accompanied by defective T cell-
mediated immunity (15, 16). It is well known that CD4 andCD8T
cells are involved in the viral clearance during primary and sec-
ondary IAV infection (17). Moreover, several reports have dem-
onstrated the essential role of lung-resident IAV-specific memory
CD4 and CD8 T cells, which express lung-retentive markers such
as CD11a, CD49d, and CD103, in optimal disease control during
IAV infection (18, 19). Meanwhile, these tissue-resident memory
(TRM) cells in the lung also confer broad immunity against heter-
ologous IAV infection. For instance, preexisting influenza virus-
specific CD4 T cells in healthy humans induce a heterotypic im-
mune response after IAV challenge, which was correlated with
disease protection with less severe illness (20). These heterologous
CD4 TRM cells would control the IAV infection via induction of
cross-reactive IAV-specific immunity (21) and/or production of
innate-like cytokines and chemokines during IAV infection (22).
However, although the role of IAV-specific memory T cells in the
lung is relatively well-established, the impact of bystander-acti-
vated, antigen-nonspecificmemory T cells in the lung during IAV
protection remains elusive (23). Since optimal protection from
IAV infection requires orchestration of the immune response by T
cells in the mucosal site, it would be intriguing to investigate
whether augmentation of pulmonary T cell-mediated immunity
without administration of cognate antigen can also provide po-
tential benefit to the host during IAV infection.
In this study, we investigated the prophylactic effects of inter-
leukin-7 (IL-7) against lethal IAV infection. IL-7 is known to in-
duce expansion of T cells under lymphopenic conditions (24). In
our previous studies, we demonstrated that IL-7 can be used as a
vaccine adjuvant to augment antigen-specific T cell response (25,
26) and to enhance antibody responses through the induction of
follicular helper T cells (27). Here, we demonstrate that a single
intranasal pretreatment with Fc-fused IL-7 (IL-7–mFc), but not a
native form of IL-7, completely protects mice from IAV-induced
mortality for an extended period of time, evenwithout preexisting
IAV-specific immunity. IL-7–mFc treatment alters immune envi-
ronments in the lung,with prolonged occupancy of lung-retentive
effector/memory phenotype T (TRM-like) cells, which play an es-
sential role in protection from IAVs by limiting viral replication
and immunopathology, while helping IAV-specific cytotoxic T
lymphocytes (CTLs) to propagate. Among pulmonary T cell pop-
ulations expressing IL-7 receptor (CD127), CD4 TRM-like cells
appeared to be crucial for protective functions generated by IL-7–
mFc. Collectively, our data show a novel prophylactic function of
IL-7–mFc against IAV infections, highlighting an immune-mod-
ulatory role of pulmonary T cells.
MATERIALS AND METHODS
Animals. Female BALB/c, BALB/c-nude, C57BL/6, and FcRn/ mice
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)
and housed under specific-pathogen-free conditions in an approved ani-
mal facility at Pohang University of Science and Technology (POSTECH)
Biotech Center and International Vaccine Institute (Seoul, Republic of
Korea). All mouse experiments were performed in accordance with Na-
tional Institutes of Health guidelines, and protocols were approved by the
Institutional Animal Care and Use Committee (IACUC).
Preparation and treatment. The murine nonlytic Fc-fused IL-7 and
nonlytic Fc fragment were prepared as previously described (28). Recom-
binant human IL-7 (IL-7) was purchased from Shenandoah Biotechnol-
ogy (Warwick, PA, USA). After being anesthetized with ketamine (100
mg/kg; Yuhan, Republic of Korea) and xylazine hydrochloride (10mg/kg;
Bayer, Belgium) in phosphate-buffered saline (PBS) intraperitoneally
(i.p.),mice received 50l of the indicated doses of cytokines in PBS via the
indicated routes with a micropipette or syringe. The depletion monoclo-
nal antibodies (MAbs) against mouse CD4 (GK1.5), CD8 (2.43), V2
(UC3-10A6), and polyclonal rat IgG were purchased from Bioxcell (West
Lebanon, NH, USA). Mice received 200 g of each depletion MAb i.p.
at1, 0, 1, and 4 days after IAV infection.
Virus infection and titration. Influenza virusH1N1 (A/Puertorico/8/
34) and H5N2 (A/aquatic bird/ma81/2007) strains were kindly provided
by Young Ki Choi (Chungbuk National University of Medicine, Republic
of Korea). Mouse-adapted H5N2 was generated by passaging the H5N2
A/Aquatic bird/Korea/W81/05 strain as described previously (29). At the
indicated time point after IL-7–mFc treatment, mice were anesthetized
and infected intranasally (i.n.) with 3 50% lethal doses (LD50) of PR8 or
H5N2. Body weight change and survival were monitored daily following
infection, and groups withmore than 50% deadmice were excluded from
the body weight graph. Mice that lost more than 30% of their initial body
weight were euthanized.
Tomeasure virus titers, total lung homogenate samples taken at 3 and
7 days postinfection (dpi) were added to a monolayer of Madin-Darby
canine kidney (MDCK) cells in quadruplicate with 10-fold serial dilution,
and the cytopathic effects were monitored daily. Virus titer was deter-
mined with a hemagglutinin test and calculated by the method of Reed
and Muench, as previously described (30). Virus titer was expressed as
log10 of the 50% tissue culture infective dose (TCID50) per milliliter.
BALF collection and lung homogenate preparation. The mice were
anesthetized, and bronchoalveolar lavage fluid (BALF) was collected with
1 ml of PBS. After BALF collection, the lungs were collected, minced into
small pieces, and treated with type I collagenase (Gibco/Life Technology,
Grand Island, NY, USA) and DNase I (Sigma-Aldrich, St. Louis, MO,
USA) at 37°C for 30 to 45 min. Tissue fragments were harvested and
crushed through a 70-m strainer (BD Biosciences/Falcon, San Jose, CA,
USA) to generate single cell suspensions. The cells were then washed and
resuspended with RPMI 1640 (Welgene, Republic of Korea) containing
10% fetal bovine serum (FBS) (HyClone, South Logan, UT, USA), 2-mer-
captoethanol (Gibco), and antibiotics (Gibco).
Quantification of cytokines, chemokines, influenza virus-specific
antibodies, and total proteins in BALF and serum. The levels of cyto-
kines and chemokines were first screened with a Milliplex MAP mouse
cytokine/chemokine kit (Millipore, Billerica, MA, USA) and further ana-
lyzed using DuoSet enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN, USA) for mouse gamma interferon
(IFN-), IL-6, G-CSF,MCP-1, and IP-10 according to themanufacturer’s
protocol. Total protein concentrations in the BALF were quantified using
protein assay dye reagent (Bio-Rad, Hercules, CA, USA) with bovine se-
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rum albumin (BSA) (Roche, Germany) as a standard. To quantify the
level of influenza virus-specific antibodies, total IgG and IgA were ana-
lyzed by direct ELISAwith inactivatedH5N2 virus. Total IgG-horseradish
peroxidase (IgG-HRP) and IgA-HRPwere purchased from Southern Bio-
tech (Birmingham, AL, USA).
Flow cytometry. Single-cell suspensions of lung homogenate were
incubated with Fc blocker (2.4G2; eBioscience, San Diego, CA, USA) in
staining buffer (1% FBS in PBS) to prevent nonspecific antibody binding.
The cells were then stained with MAbs against B220, CD3, CD4, CD8,
CD11a, CD11b, CD11c, CD44, CD49d, CD62L, CD69,DX5, F4/80, Ly6C,
major histocompatibility complex (MHC) II, IFN-, T cell receptor 
(TCR), and 7-aminoactinomycin D (7-AAD) (all from eBioscience)
and with MAbs against CD19, CD45, Gr-1, and Ly6G (all from BD Bio-
sciences). For the intracellular cytokine staining of IFN--producingCD8
T cells, lung homogenates were incubated for 6 h with hemagglutinin
(HA) peptide (residues 529 to 543; Peptron, Republic of Korea), brefeldin
A (eBioscience), and DNase I (Sigma) and then stained using Cytofix/
Cytoperm following the manufacturer’s protocol (BD Bioscience). All
samples were analyzed with LSR Fortessa (BD Biosciences) and FlowJo
software (Tree Star, Ashland, OR, USA).
FIG 1 Protective effect of IL-7–mFc against lethal influenza virus infection. (A) Mice (BALB/c, n 8 mice per group) were treated with 1 g of IL-7–mFc via
the indicated routes. At 14 days after the treatment, themice were infected with 3 LD50 of H5N2. (B)Mice (BALB/c, n 6mice per group) received the indicated
dose of IL-7–mFc, IL-7, or PBS intranasally and then were infected with 3 LD50 of H5N2 14 days later. (C) C57BL/6 and FcRn
/mice (n 8 mice per group)
were administered PBS or 1 g of IL-7–mFc intranasally. At 14 days after treatment, the mice were infected with 3 LD50 of H5N2 virus. (D) The mice (BALB/c,
n 11 mice per group) received 1 g of IL-7–mFc intranasally at the indicated time points prior to the infection. All groups of mice were then simultaneously
infected with 3 LD50 of H5N2 at day 0. The survival rate was analyzed by the Kaplan-Meier method. The results are representative of more than two independent
experiments with similar results. ††, P 0.01 by log-rank test.
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In vivo antibody labeling. To analyze the pulmonary residency of T
cells, we treatedmice with PBS or 1g of IL-7–mFc intranasally. At 7 and
14 days after IL-7–mFc treatment, mice were injected with 2.5 g of anti-
mouse CD3e-peridinin chlorophyll protein (PerCP)-Cy5.5 (BD biosci-
ence) intravenously at 10 min prior to sacrifice as previously described
(31). Residual antibody was removed by cardiac perfusion with PBS, and
the lung resident T cell populations in single-cell suspensions of lung
homogenate were analyzed by flow cytometry.
Histological analysis and inflammation score. Mice were anesthe-
tized, and the lungs were prepared via thoracotomy and transcardial per-
fusion with ice-cold PBS. Perfused lungs were immediately fixed with 4%
paraformaldehyde, kept at 4°C overnight, and embedded into paraffin.
Lung sections were then stained with hematoxylin and eosin (H&E) solu-
tion (Sigma-Aldrich). The images of whole lung tissues were captured
with a PannoramicMIDI slide scanner (3DHISTECH,Hungary). Pulmo-
nary inflammation was assessed by the degree of peribronchiolar and
perivascular inflammation, as previously described (32).
mRNApreparation, cDNA synthesis, and qPCRanalysis of lung ho-
mogenate.After preparation of lung homogenate, mRNAswere prepared
with a Reliaprep mRNA preparation kit (Promega, Fitchburg, WI, USA),
and cDNAs were synthesized with the GoScript reverse transcriptase sys-
tem (Promega) according to the manufacturer’s protocol. Quantitative
PCR (qPCR) assay was performed using Power SYBR green master mix
(Applied Biosystems, Foster City, CA). The following primers for qPCR
analysis were synthesized by Genotech (Republic of Korea): NS-1 for-
ward, TGCGGGAAAGCAGATAGTGG; NS-1 reverse, TCAGTTAGGTA
GCGCGAAGC; L32 forward, GAAACTGGCGGAAACCCA; and L32 re-
verse, GGATCTGGCCCTTGAACCTT. Relative expression levels of
H5N2 NS-1 mRNA were normalized to the level of L32 mRNA.
Statistical analysis.A two-tailed Student t test was used to evaluate the
differences between two groups. A one-way analysis of variance
(ANOVA) with Bonferroni’s posttest was used for more than three
groups. Differences in survival rates between groups were determined by
a log rank test.
FIG 2 Protective effect of IL-7–mFc against infection with other strains of IAV. The mice (BALB/c, n 6 mice per group) were infected with a lethal dose of
A/PR/8/34 H1N1 (A), A/California/04/09 H1N1 (B), or A/Philippines/2/82 H3N2 (C) at 14 days after intranasal IL-7–mFc treatment. The average body weight
loss is shown as a percentage of initial weight at the time of infection (mean  standard error of the mean [SEM]). The survival rates were analyzed by the
Kaplan-Meier method. The results are representative of two independent experiments with similar results. †, P 0.05; ††, P 0.01 (by log rank test).
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Intranasal pretreatment of Fc-fused IL-7 protects mice from le-
thal IAV infection. To investigate the protective effect of IL-7 on
lethal IAV infection and its route dependency, BALB/c mice were
treated with 1 g of IL-7–mFc through various routes and then
infected with 3 LD50 of mouse-adaptive avian influenza virus
(H5N2, A/Aquatic bird/Korea/ma81/2005) at 2 weeks after IL-7–
mFc treatment. Of note, intranasal IL-7–mFc treatment com-
pletely protected mice against lethal influenza virus infection,
whereas IL-7–mFc treatment via an intraperitoneal, subcutane-
ous, or intramuscular route showed no significant protection (Fig.
1A). This finding indicated that induction of local immune re-
sponses by IL-7–mFc at the pathogen entry site, namely, the air-
way mucosa, may be critical for protection against lethal IAV in-
fection.
To define an optimal dose of IL-7–mFc for protection against
lethal IAV infection, we treated mice with IL-7–mFc at multiple
doses ranging from 0.04 g to 10 g. We observed no significant
protectionwith 0.04g, partial protectionwith 0.2g (50%of the
mice survived), and complete protection with more than 1 g of
IL-7–mFc (Fig. 1B). Interestingly, treatment with recombinant
human IL-7 (IL-7) did not provide protection at any tested doses
(1 g, 3 g, and 10 g for IL-7) (Fig. 1B). In addition, intranasal
pretreatment with 1 g of Fc fragment exhibited no significant
protective effect (data not shown). Altogether, these data suggest a
critical role of Fc-fused IL-7, but not Fc fragment itself, in the
protection against IAV infection.
To further evaluatewhether Fc fusion to IL-7 is required for the
protective function, we tested IL-7–mFc in neonatal Fc receptor-
deficient (FcRn/) mice. Remarkably, IL-7–mFc-mediated pro-
tection against IAV infection was completely abrogated in
FcRn/ mice (Fig. 1C). This finding indicates that an efficient
transport of IL-7–mFc into the airway mucosa through FcRn is
critical for protection from IAV infection, as intranasal delivery of
Fc-fused mucosal vaccines induced protective immune responses
by the FcRn-dependent transcellular transport (33). Based on
these results, we administered 1 g of IL-7–mFc intranasally at 2
weeks prior to IAV infection in subsequent experiments as a stan-
dard protocol for evaluating its protective function.
IL-7–mFcpretreatment exhibits a long-termprophylactic ef-
fect against lethal IAV infection. To investigate whether IL-7–
mFc treatment confers a prolonged protective function against
lethal IAV infection, we infected mice at different time points
from 0 to 35 days after intranasal delivery of IL-7–mFc (Fig. 1D).
The protective effect of IL-7–mFc was observed 5 days after IL-7–
mFc treatment, but not from 0 to 3 days. Remarkably, complete
protection against IAV was achieved at 7 days and even at 14 days
after IL-7–mFc treatment. This protective effect was diminished
over time but was still significant until 35 days, with 63% and 36%
of mice surviving when infected at 21 days and 35 days after IL-7–
mFc treatment, respectively. To determine whether IL-7–mFc
treatment is able to exert protection against different IAV strains,
we pretreated mice with PBS or IL-7–mFc and infected themwith
lethal doses of H1N1 (A/Puerto Rico/8/34 and A/California/04/
09) and H3N2 (A/Philippines/2/82) strains. Pretreatment with
IL-7–mFc at 14 days prior to challenge gave protection from a
lethal infection of the tested IAVs, suggesting that IL-7–mFc-me-
diated IAV protection is independent of the viral strain (Fig. 2A
to C).
IL-7–mFc treatment induces the lung-resident memory T
cells required for protection from IAV infection. CD127, the
receptor for IL-7 (IL-7R	), is important for the survival and pro-
liferation of T cells (24). Thus, we analyzed pulmonary lympho-
cyte populations from 0 to 35 days after intranasal IL-7–mFc ad-
ministration to address whether IL-7–mFc affects pulmonary T
cells. In fact, IL-7–mFc significantly increased the absolute num-
ber of CD127-expressing immune cells, including CD4, CD8, and
T cells and B cells (Table 1). This overall increase of pulmonary
immune cells peaked at day 7 and gradually waned over time. An
expansion of pulmonary immune cells in general almost disap-
peared at 14 days after IL-7–mFc treatment, although an increase
of  T cells still remained until 21 days.
Of note, the numbers of CD4 and CD8 T cells displaying an
effector/memory T cell phenotype (CD62Llow CD44high) were sig-
nificantly increased at day 7 after IL-7–mFc treatment (Table 1).
In addition, those CD4, but not CD8, T cells remained at the lung
until day 21. Interestingly, those T cells express CD11a andCD49d
(data not shown), both of which are known as lung-retentive
markers for T cells (34). Furthermore, we conducted in vivo anti-
body labeling experiments to clarify that the pulmonary T cells are
actually lung retentive (35). At 7 and 14 days after PBS or IL-7–
mFc treatment, a fluorescence-conjugated antibody against CD3
was administered intravenously to mice 10 min before perfusion
and harvest of the lung tissue.We found that intranasal treatment
with IL-7–mFc could significantly increase the pulmonary CD4
and CD8 T cells that “protected” against in vivo antibody labeling
(data not shown), indicating that treatment with IL-7–mFc in-
creased lung-resident T cells. Interestingly, the number of “la-
beled” T cells returned to the basal level, while that of “protected”
T cells still showed a significant increase at 14 days after IL-7–mFc
TABLE 1 Kinetics of pulmonary immune cells after intranasal IL-7–mFc treatment
Cells
Absolute cell numbers on day after IL-7–mFc treatmenta:
0 3 7 14 21 35
Total CD4 T (
106) 0.68 0.07 0.76 0.03 2.08 0.28** 0.89 0.19 0.79 0.14 0.70 0.07
CD62Llo CD44high CD4 T (
105) 0.58 0.08 1.44 0.08** 7.80 1.24** 1.61 0.25** 0.93 0.05** 0.69 0.05
Total CD8 T (
106) 0.31 0.07 0.32 0.01 0.75 0.11** 0.42 0.08 0.36 0.08 0.28 0.03
CD62Llo CD44high CD8 T (
105) 0.18 0.03 0.29 0.02* 1.22 0.14** 0.50 0.12* 0.25 0.03 0.26 0.04
 T (
105) 0.24 0.02 0.39 0.01** 4.71 0.59** 0.54 0.16** 0.40 0.06* 0.38 0.02**
B (
106) 0.84 0.17 0.97 0.03 2.27 0.38* 1.13 0.10 0.83 0.18 ND
NK (
106) 0.36 0.03 0.58 0.03* 0.71 0.07** 0.39 0.04 0.29 0.05 ND
a Mice received 1 g of IL-7–mFc intranasally at 0, 3, 7, 14, and 21 days prior to sacrifice. Absolute numbers of immune cells in the total lung homogenates at each indicated time
point were calculated based on the percentage of total cell number with flow cytometry. The results are representative of two independent experiments and are expressed as the
mean SEM for four mice per group. ND, not determined. *, P 0.05; **, P 0.01 (by Student’s t test, compared with cell numbers on day 0).
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FIG 3 Effect of intranasal IL-7–mFc pretreatment on pulmonary T cells and viral titer in the BALF after IAV infection. BALB/cmice were treated with IL-7–mFc
intranasally and infected with 3 LD50 of H5N2 after 14 days. (A) Absolute numbers of T cells from total lung homogenates at 3 dpi and 7 dpi were measured. (B)
Frequencies of the CD62Llow CD44high population of CD8 and CD4 T cells were analyzed at 7 dpi. (C) Absolute numbers of pulmonary B and NK cells were
measured at 3 dpi and 7 dpi. (D)H5N2-specific IgG titers in the BALF and serumwere analyzed at 7 dpi. (E and F)Virus titers (E) and relative expression ofH5N2
NS-1 mRNA (normalized by housekeeping gene L32) in total lung homogenates (F) were analyzed at 3 dpi and 7 dpi. The bars indicate the mean SEM for 6
mice per group. Representative data from more than two independent experiments are shown. *, P 0.05; **, P 0.01 (by Student’s t test). White bars, PBS
control group; black bars, IL-7–mFc-treated group.
Kang et al.
2278 jvi.asm.org March 2016 Volume 90 Number 5Journal of Virology
 o
n
 April 7, 2016 by PO
HANG
 UNIVERSITY O









treatment compared to control values. Moreover, the protected
CD4 T cells after IL-7–mFc treatment preferentially exhibited an
effector/memory phenotype, while both naive and effector/mem-
ory phenotype CD8 T cells were protected by antibody labeling
(data not shown). Altogether, these characteristics of pulmonary
T cells recruited by IL-7–mFc treatment are reminiscent of tissue-
resident memory T (TRM) cells, albeit a polyclonal population.
Thus, we here describe those cells as TRM-like cells. We also found
that both CD4 and CD8 T cells were significantly increased in the
mediastinal lymph nodes, but not in the spleen, at 7 days after
IL-7–mFc treatment (data not shown). Interestingly, a retention
of IL-7-primed T cells, in particular CD4 T cells, in the lung cor-
related with a prolonged protective activity of IL-7–mFc against a
lethal IAV infection (Fig. 1D), which provides a possibility that
TRM-like cells residing in the local pulmonary site may contribute
to IL-7–mFc-mediated protection.
Analogously, the absolute numbers of pulmonary T cells, such
as CD8, CD4, and T cells, were increased after IAV infection by
IL-7–mFc pretreatment compared to PBS treatment (Fig. 3A).
Moreover, activated CD8 and CD4 T cells having an effector/
memory phenotype were significantly increased in IL-7–mFc-
treated mice (Fig. 3B). In contrast, there was no significant differ-
ence in the number of pulmonary NK cells (CD3 panNK)
between PBS- and IL-7–mFc-treated mice (Fig. 3C). Although
pulmonary B cells were slightly increased by IL-7–mFc pretreat-
ment, IAV-specific IgG production in the BALF and serum was
not further upregulated (Fig. 3C and D). This indicates that NK
cells and IAV-specific IgGmight not be associatedwith IL-7–mFc-
mediated protection from lethal IAV infection.
Next, we measured virus titers in the total lung homogenate to
determine whether IL-7-primed pulmonary T cells are associated
with clearance of virus. Viral titers in the total lung homogenates
of the IL-7–mFc-treated group were decreased at both 3 and 7 dpi
compared to those in the PBS control group, although statistical
significance was observed at 3 dpi (Fig. 3E). In parallel, the expres-
sion level of H5N2 NS-1 mRNA was significantly reduced in the
FIG 4 Effect of IL-7–mFc on IAV-induced pulmonary pathology. BALB/c mice were treated intranasally with IL-7–mFc and then infected with 3 LD50 of H5N2
after 14 days. (A)H&E staining of lung sections at amagnification of
50 (left) and total inflammatory scores (right) at 7 dpi. Scale bars, 1mm. (B) Total protein
concentration in the BALF at 7 dpi. (C) Levels of inflammatory cytokines and chemokines in the BALF at 3 dpi and 7 dpi. (D) Numbers of neutrophils,
monocytes, and macrophages analyzed by flow cytometry at 3 dpi and 7 dpi. The bars indicate the mean SEM for 8 mice per group. Representative data from
more than three independent experiments are shown. *, P 0.05; **, P 0.01 (by Student’s t test). H&E, hematoxylin and eosin.White bars, PBS control group;
black bars, IL-7–mFc-treated group.
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total lung homogenates of IL-7–mFc-treated mice (Fig. 3F). Col-
lectively, these results demonstrate that IL-7–mFc pretreatment
generates TRM-like cells in the lung, which subsequently acceler-
ates pulmonary T-cell responses upon infection, leading to pro-
tection from IAV.
IL-7–mFc-primed mice show reduced pulmonary immuno-
pathology after IAV infection. Because we observed a profound
survival benefit from a single intranasal pretreatment of IL-7–mFc
and with early control of viral infection, we next evaluated the
pulmonary immunopathology induced by infection. The histo-
pathological parameters for airway inflammation at 7 dpi were
significantly reduced in the lungs of mice given IL-7–mFc pre-
treatment compared to PBS-treated mice (Fig. 4A). Accordingly,
the total protein concentration in the BALF, which is one of the
hallmarks of airway inflammation and tissue destruction, was also
decreased in IL-7–mFc-treated mice (Fig. 4B).
Because an excessive production of cytokines and chemokines
after IAV infection correlates with severe pulmonary pathology
following mortality (9, 36), we examined the levels of various in-
flammatory cytokines and chemokines in the BALF after infec-
tion. The levels of IFN-, IL-6, G-CSF, MCP-1, and IP-10 in the
BALF were significantly reduced in IL-7–mFc-treated mice com-
pared to PBS-treated controls at both 3 and 7 dpi (Fig. 4C). More
importantly, the number of pulmonary neutrophils (Gr-1high
Ly6clow CD11b) was sharply decreased in IL-7–mFc-treated
mice at 3 and 7 dpi (Fig. 4D). In addition, the numbers of mono-
cytes (CD11b CD11c Ly6c) and inflammatory macrophages
(CD11bCD11cMHCIILy6c F4/80)were also decreased at
3 dpi in IL-7–mFc-treated mice (Fig. 4D). These results agree well
with a previous report that an increase in myeloid-lineage cells,
including neutrophils, monocytes, and inflammatory macro-
phages, in the lung directly correlates with the severity of IAV-
induced pathology (10). Of note, a dramatic decrease of neutro-
phils at 7 dpi in the IL-7–mFc-treated group likely contributes to
reduced IAV-induced mortality (37). Thus, we focused on neu-
trophil infiltration as a main feature of IAV-induced pathology in
further studies.
T cells are required for IL-7–mFc-mediated protection from
IAV infection. To investigate whether T cells directly contribute
to reduced pulmonary pathology and subsequent protection from
IAV infection by IL-7–mFc pretreatment, we used athymic nude
(BALB/c-nude) mice. In an obvious contrast to wild-type (WT)
mice, IL-7–mFc treatment in BALB/c-nude mice could not confer
protection from lethal IAV infection, although it provided a slight
increase in median survival for 2 days, compared to that in PBS-
treated controls (Fig. 5A). In parallel, the levels of cytokines and
chemokines in theBALFwerenot significantly changedby IL-7–mFc
pretreatment in nude mice, except for G-CSF, albeit the expression
scale of individual molecules in nude mice appeared somewhat dif-
ferent from that in WT mice, in particular for IFN-, which is a
typical T cell-mediated cytokine (Fig. 5B). Consistently, IL-7–mFc
pretreatment did not reduce the number of pulmonary neutrophils
innudemiceupon infection (Fig. 5C).Together, these results suggest
that T cells are required for IL-7–mFc-mediated protection against
IAV infection and that pulmonary T cells stimulated with IL-7–mFc
seem to reduce the severity of immunopathology.
CD4TRM-like cells are essential for theprotective functionof
IL-7–mFc against IAV infection.To further determine the role of
specific T cell subsets in IL-7–mFc-mediated protection against
IAV infection, depletion antibodies for CD4, CD8, and  T cells
FIG 5 Effect of intranasal IL-7–mFc pretreatment on protection against IAV infection in BALB/c-nude mice. BALB/c-nude andWT BALB/c mice were treated
with PBS or IL-7–mFc and infected with 3 LD50 of H5N2. (A) Weight loss and survival. Average body weight loss is shown as the mean SEM for 10 mice per
group, and the survival rate was analyzed by the Kaplan-Meier method. The data are representative of two independent experiments. †, P 0.05; ††, P 0.01
(by log rank test). (B) The levels of inflammatory cytokines and chemokines in the BALF were analyzed by ELISA. (C) The numbers of pulmonary neutrophils
were analyzed at 7 dpi by flow cytometry. The results are expressed as the mean SEM for 8 mice per group. The data are representative of two independent
experiments with similar results. *, P 0.05; **, P 0.01 (by Student’s t test). White bars, PBS-treatedWTmice; black bars, IL-7–mFc-treatedWTmice; white
bars with horizontal lines, PBS-treated BALB/c-nude mice; white bars with vertical lines, IL-7–mFc-treated BALB/c-nude mice.
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FIG 6 Involvement of CD4 T cells in IL-7–mFc-mediated regulation of immunopathology after lethal IAV infection. (A) Mice (BALB/c, n 18) were treated
with IL-7–mFc and infected with 3 LD50 of H5N2 after 14 days. Then, 200 g of anti-CD4, anti-CD8, anti-TCR, or isotype MAb was injected i.p. four times
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were used (Fig. 6A). While depleting  T cells with an anti-
TCR (V2, GV3S1) MAb had no impact on protection, treat-
ment with anti-CD8MAb significantly impeded IL-7–mFc-medi-
ated protection (61% of mice survived at 20 dpi). Indeed, we
observed a significant increase of IAV-specific CD8 T cells, mea-
sured by IFN- production upon stimulationwithHA529–543 pep-
tide, in the lungs of IL-7–mFc-treated mice (Fig. 6B). Since virus-
specific CD8 T cells play an essential role in protection from IAV
infection (38), our data suggest that IAV-specific pulmonary CD8
T cells, augmented by IL-7–mFc pretreatment, contribute to pro-
tection by clearance of IAV to some extent. More importantly,
depleting CD4 T cells with an anti-CD4 MAb markedly impaired
the protective activity of IL-7–mFc (22% of mice survived at 20
dpi) compared to depletingCD8T cells, with the differences being
almost statistically significant (P  0.0575 by the log rank test)
(Fig. 6A). We confirmed that treatment with depletion antibodies
against CD4 and CD8 resulted in nearly complete depletion of pul-
monary T cells (data not shown). Again, decreases of inflammatory
mediators andpulmonaryneutrophils causedby IL-7–mFcwerenul-
lified by anti-CD4 treatment (Fig. 6C and D). Furthermore, the en-
hanced number of IAV-specific CD8 T cells induced by IL-7–mFc
returned to thebasal level after anti-CD4treatment (Fig. 6E), suggest-
ing a CD4T cell help for CD8T cell responses in the lung. Notably, a
single treatment with anti-CD4 at 1 dpi abolished the protective ac-
tivity of IL-7–mFc, while treating with anti-CD4 at later time points,
such as 4 dpi and 7 dpi, showed no effects on protection (Fig. 6F).
Together, these data suggest that lung-retentive CD4 TRM-like cells
play a main role in the IL-7–mFc-mediated protective function
against IAV infection by modulation of IAV-induced immunopa-
thology as well as augmenting CD8 T cell responses and that IL-7-
primed CD4 TRM-like cells exert their immune-modulatory roles at
an early stage of IAV infection.
DISCUSSION
In this study, we demonstrated that intranasal introduction of IL-7–
mFc into naivemicemodulates immune environments of the airway
mucosa, which protects them from a lethal infectionwith IAV. IL-7–
mFc, prior to infection, induces a prolonged maintenance of TRM-
like cells in the lung,which are subsequently responsible for reducing
viral replication and enhancing antiviral T cell responses postinfec-
tion, leading to reduction of immunopathology and mortality from
IAV. Our data provide a novel way of immune modulation in the
lung, suggesting intranasal delivery of IL-7–mFc as a prophylaxis
against highly pathogenic IAV infection.
The recruitment and residency of pulmonary T cells by IL-7–
mFc, in particular CD4 T cells, play an essential role in the long-
lasting protection against IAV. In naivemice before IAV infection,
intranasal treatment with IL-7–mFc increased pulmonary T cells
displaying phenotypic attributes of naive (CD62Lhigh CD44low) or
effector/memory (CD62Llow CD44high) T cells. Although both cell
types were increased in the lung by IL-7–mFc, the extent of expan-
sion and long-termmaintenance wasmore prominent in effector/
memory phenotype T cells, which we designate TRM-like cells in
this study. It is unlikely that IL-7–mFc preferentially affects
TRM-like cells, since previous reports have shown that both
naive and memory T cells express CD127, with their prolifera-
tive capacities by IL-7 being comparable (39, 40). Since we
found that TRM-like cells, but not naïve cells, exhibited expres-
sion of CD11a and CD49d and protected against in vivo anti-
body labeling (data not shown), it is tempting to speculate that
both naive and effector/memory phenotype populations are
expanded and recruited by IL-7–mFc treatment, but that only
effector/memory phenotype cells may reside as TRM-like cells
in the lung for an extended period of time by elevated cell
adhesion molecules, while naive T cells simply pass by the lung
within the microvasculature, returning to circulation. Longer
pulmonary residency of CD4 TRM-like cells than of CD8 cells is
also notable, albeit the expression levels of lung-retentive
markers in both cell types appeared to be comparable. Given
that the protective function of IL-7–mFc against IAV was ob-
served only with intranasal delivery, these changes of T cell
composition in the local immune environment at the airway
mucosa seem to be critical for its prophylactic effects.
Preoccupied pulmonary TRM-like cells after IL-7–mFc treat-
ment, although not antigen specific, help IAV-specific T cells
thrive upon infection. An increase of effector CD8 T cells in the
lung was prominent postinfection to clear viruses, and further-
more, preexisting CD4 TRM-like cells appeared to be essential for
expansion of newly generated IAV-specific CD8 cells. Those ex-
panded antigen-specific CTLs may contribute to directly control
viral clearance in the end, as shown previously (41). Indeed, the
number of IAV-specific CTLs was reversely correlated with all
attributes of IAV-induced pulmonary pathology at 7 dpi, such as
airway inflammation, production of inflammatory mediators,
and infiltration of neutrophils. However, depletion of CD8 cells
displayed less profound effects on protection from IAV than that
of CD4 cells. Therefore, both CD4 and CD8 T cells are necessary
for the IL-7–mFc-mediated prophylaxis, but CD4 T cells play a
dominant role. It is likely that antigen-specific T cells are not re-
sponsible for early control of viral replication at 3 dpi, since we
failed to observe IAV-specific CD8 T cells in the lung at this time
point (data not shown). Rather, we speculated that the IL-7-
primed TRM-like cells, in particular CD4 cells, played an impor-
tant role in primary control of viruses during the early stage of IAV
infection. This might explain a correlation between preoccupancy
of pulmonary CD4 TRM-like cells achieved by IL-7–mFc treat-
ment before infection and a prolonged survival benefit against
lethal IAV postinfection.
at 1 dpi, 0 dpi, 1 dpi, and 4 dpi. Weight loss and survival curves were analyzed by combining two independent experiment with 9 mice per group. (B)
Intracellular cytokine staining for HA529–543-specific IFN- production of CD8 T cells from total lung homogenates was analyzed at 7 dpi. HA-specific IFN-
production was calculated as the difference in IFN- CD8 T cells between groups with HA529–543 and no stimulation. Representative dot plots (left) and
summary graphs (right) are shown. **, P 0.01 by Student’s t test.White bars, PBS control; black bars, IL-7–mFc-treated group. (C to E) Levels of inflammatory
cytokines and chemokines in BALF (C), number of pulmonary neutrophils (D), andHA529–543-specific IFN- production byCD8T cells (E) inmice treatedwith
IL-7–mFc after administration of anti-CD4 and IgG control at 7 dpi. The results are representative of three independent experiments and are expressed as the
mean  SEM for 8 mice per group. **, P  0.01 by one-way ANOVA with Bonferroni’s posttest. White bars, IL-7–mFc with IgG control; white bars with
horizontal lines, IL-7–mFc with IgG control; black bars, IL-7–mFc with anti-CD4MAb treatment. (F)Mice (BALB/c, n 6 per group) were intranasally treated
with IL-7–mFc and infected with a lethal dose of H5N2 after 14 days.Mice were treated with anti-CD4MAb at 1 day, 4 days, or 7 days after IAV infection.Weight
loss and survival rates are shown. The data are representative of two independent experiments. ††, P 0.01 by log rank test.
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It is well known that IAV-specific memory CD4 T cells con-
tribute to develop protective immune responses against respira-
tory viral infection (42). On the one hand, typical secondary recall
responses to antigens by memory CD4 T cells in the lung partici-
pate in direct viral clearance (43). On the other hand, memory
CD4 T cells have been shown to induce innate immune responses,
producing inflammatory cytokines and chemokines in the lung,
for early control of viral replication (22, 44). Cognate viral antigen
was required for those innate-like functions of memory CD4 T
cells in one study, but antigen independency was also observed in
the other. In this regard, we speculate that pulmonary CD4 TRM-
like cells induced by IL-7–mFc may also direct innate responses
for early control of IAV in our study. Furthermore, those CD4
TRM-like cells are a naturally occurring polyclonal population, but
not IAV specific, since IL-7–mFc was introduced prior to IAV
challenge. Thus, IL-7-primed TRM-like cells would be different
from the IAV-specific TRM cells described in previous studies, but
they might share some functional characteristics. This suggests
that cognate antigen may be dispensable for their innate func-
tions, while bystander activation of polyclonal CD4 TRM-like cells
via IAV infection can play a role. One possible limitation of our
study is that depletion with antibodies to T cells to investigate the
role of TRM-like cells could also abrogate the normal primary T
cell responses against IAV, which unarguably contribute to pro-
tection. Thus, an ideal experimental condition should be abrogating
T cell compartments during the period after posttreatment with IL-
7–mFc and prior to IAV challenge to dissect the relative contribution
of IL-7-primed TRM-like cells more specifically. However, the recov-
ery of the normal CD4T cell compartment after depletionwith anti-
bodyneeds approximately 100days (45).Therefore, itwouldbe tech-
nically difficult to achieve a removal of T cells within a specific
window of time by using depletion antibodies. However, developing
alternativemethods for proving the relative contribution of preoccu-
pied IL-7-primed TRM-like cells with intact primary T cell responses
will be valuable for future study.
A full prophylactic effect of IL-7–mFc against IAV is achieved
when it is introduced 1 or 2 weeks a prior to infection. Since we
infused IL-7–mFc in the lung in otherwise unprimednaivemice, it
may take time for IL-7–mFc to alter the immune environment in
the lung by recruiting and modulating pulmonary T cells, which
subsequently exert protective functions postinfection. Further,
IL-7–mFc treatment along with IAV infection simultaneously did
not confer protection (Fig. 1D), raising an issue for using it as a
therapeutic modality. However, humans likely have lung-resident
T cells in the airway mucosa which are generated by previous
episodes of vaccination and infection, including with seasonal in-
fluenza viruses (20). Therefore, further study is needed to address
the therapeutic potential of IL-7–mFc against IAV infection in mice
having preexisting pulmonaryT cells that are specific to homologous
orheterologousvirusesorevenenvironmental antigens. In this study,
we fused IL-7 to the murine Fc portion, which confers an increased
half-life in vivo through FcRn-mediated recycling (46). Moreover,
expression of FcRn in the lung epithelium enhances transcytosis of
IL-7–mFc (47), which is indispensable for immune modulation in
the lung. Thus, this approachwith Fc fusion to immune-modulatory
moleculeswouldbepromising for immune regulationat themucosal
tissues in which FcRn is expressed.
Collectively, intranasal treatment of IL-7–mFc could be a fea-
sible and promising prophylaxis for reducing influenza-induced
mortality in future pandemics and potentially could be used as a
mucosal adjuvant for IAV vaccines.
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